Department of Pharmacology and Toxicology - Institute of Pharmacy

nadine-ortner.html - nadine-ortner.html

Mag. Nadine J. Ortner, PhD 

 

  

University Assistant (Post-Doc)

Email: Nadine.Ortner@uibk.ac.at 
Phone: +43-(0)512-507 - 58815
ORCID: https://orcid.org/0000-0003-3882-3283
Graduate Program: https://cavx.at/group-ortner/

 

Molecular Pharmacology of Voltage – Gated Calcium Channels – Group

 

 

 

Research interest: I am particularly interested in deciphering the role of voltage-gated Ca²⁺ channels in brain disorders such as Parkinson’s disease, autism spectrum disorder or epilepsies and their pharmacological modulation as a potential therapeutic intervention. For my studies I employ molecular (cloning, generation of stable cell lines), electrophysiological (heterologous expression systems, brain slices), immunohistochemical and pharmacological methods.

 

For publications in Pubmed click here (link: https://www.ncbi.nlm.nih.gov/pubmed/?term=Ortner+Nadine)

 

 

 

Short curriculum

Born: April 7, 1987

2001 – 2006       Commercial academy with focus on information technology, Villach, Austria

2006 – 2012       Diploma Program in Molecular Biology, University of Vienna, Austria

2012 – 2017       PhD Program Pharmaceutical Sciences, Department of Pharmacology and Toxicology, University of Innsbruck, Austria (external member of the FWF-funded excellence PhD program “Molecular Cell Biology and Oncology (MCBO)”)

2017 – 2019       Postdoctoral research fellow, Department of Pharmacology and Toxicology, University of Innsbruck, Austria

2019 – present University assistant, Erika-Cremer habilitation fellowship of the University of Innsbruck, Austria

 

 

Scientific awards / Fellowships / Research funding

2023     Austrian Science Fund (FWF) for the study of selective Cav1.3 inhibition for the treatment of human gain-of-function CACNA1D channelopathies (project within the CavX PhD excellence program https://cavx.at/)

2021     Austrian Science Fund (FWF) for the study of the dopamine system in a neurodevelopmental disorder mouse model

2019    Habilitation fellowship of the Erika-Cremer excellence program of the University of Insbruck

2019    Poster & Travel Award (FASEB The Ion Channel Regulation Conference: Molecules to Disease, Lisbon)                           

2018    Tyrolean Science Fund (TWF) for the study of subtype-selective Inhibitors of voltage-gated Ca²⁺ channels

2017    Price by the Principality of Liechtenstein for scientific research at the University of Innsbruck

2017    Jubiläumsfonds by the University of Innsbruck and the Medical University of Innsbruck for sponsorship of scientific cooperation projects

2017    ALUMNI-I-MED Talk Prize (Life Science PhD Meeting Innsbruck, 2017)

2015    PHOENIX Pharmazie Wissenschaftspreis for the publication “Pyrimidine-2,4,6-triones are a new class of voltage-gated L-type Ca²⁺ channel activators”, Nat Commun. 2014 Jun 19;5:3897

2015    MCBO Best paper Award 2015

 

 

List of publications

Cav1.3-selective inhibitors of voltage-gated L-type Ca²⁺ channels: fact or (still) fiction?

Filippini L, Ortner NJ, Kaserer T, Striessnig J.

Br J Pharmacol. 2023 Feb 14. doi: 10.1111/bph.16060. Online ahead of print.

 

CACNA1D-Related Channelopathies: From Hypertension to Autism.

Ortner NJ.

Handb Exp Pharmacol. 2023 Jan 3. doi: 10.1007/164_2022_626. Online ahead of print.

 

Germline de novo variant F747S extends the phenotypic spectrum of CACNA1D Ca²⁺ channelopathies.

Török F, Tezcan K, Filippini L, Fernández-Quintero ML, Zanetti L, Liedl KR, Drexel RS, Striessnig J, Ortner NJ.

Hum Mol Genet. 2023 Feb 19;32(5):847-859. doi: 10.1093/hmg/ddac248.

 

β2-subunit alternative splicing stabilizes Cav2.3 Ca²⁺ channel activity during continuous midbrain dopamine neuron-like activity.

Siller A, Hofer NT, Tomagra G, Burkert N, Hess S, Benkert J, Gaifullina A, Spaich D, Duda J, Poetschke C, Vilusic K, Fritz EM, Schneider T, Kloppenburg P, Liss B, Carabelli V, Carbone E, Ortner NJ*, Striessnig J*.

Elife. 2022 Jul 6;11:e67464. doi: 10.7554/eLife.67464.

 

Calcium current modulation by the γ1 subunit depends on alternative splicing of CaV1.1.

El Ghaleb Y, Ortner NJ, Posch W, Fernández-Quintero ML, Tuinte WE, Monteleone S, Draheim HJ, Liedl KR, Wilflingseder D, Striessnig J, Tuluc P, Flucher BE, Campiglio M.

J Gen Physiol. 2022 Sep 5;154(9):e202113028. doi: 10.1085/jgp.202113028. Epub 2022 Mar 29.

 

Novel CACNA1A Variant p.Cys256Phe Disrupts Disulfide Bonds and Causes Spinocerebellar Ataxia.

Nikonishyna YV, Ortner NJ, Kaserer T, Hoffmann J, Biskup S, Dafotakis M, Reetz K, Schulz JB, Striessnig J, Dohrn MF.

Mov Disord. 2022 Feb;37(2):401-404. doi: 10.1002/mds.28835. Epub 2021 Oct 14.

 

Voltage-Gated Ca²⁺ Channels in Dopaminergic Substantia Nigra Neurons: Therapeutic Targets for Neuroprotection in Parkinson's Disease?

Ortner NJ.

Front Synaptic Neurosci. 2021 Feb 26;13:636103. doi: 10.3389/fnsyn.2021.636103. eCollection 2021.

De novo CACAN1D Ca²⁺ channelopathies: Clinical phenotypes and molecular mechanism

Ortner NJ, Kaserer T, Copeland JN, Striessnig J

Pflugers Arch. 2020 Jun 24. doi: 10.1007/s00424-020-02418-w. Online ahead of print.

 

Ca²⁺ channel blockers

Striessnig J, Ortner NJ

In: Offermanns S., Rosenthal W. (eds) Encyclopedia of Molecular Pharmacology. Springer, Cham; https://doi.org/10.1007/978-3-030-21573-6_34-1

 

Biophysical classification of a CACNA1D de novo mutation as a high-risk mutation for a severe neurodevelopmental disorder.

Hofer NT, Tuluc P, Ortner NJ, Nikonishyna YV, Fernándes-Quintero ML, Liedl KR, Flucher BE, Cox H, Striessnig J.

Mol Autism. 2020 Jan 8;11:4. doi: 10.1186/s13229-019-0310-4. eCollection 2020.

 

RBP2 stabilizes slow Cav1.3 Ca2+ channel inactivation properties of cochlear inner hair cells.

Ortner NJ, Pinggera A, Hofer NT, Siller A, Brandt N, Raffeiner A, Vilusic K, Lang I, Blum K, Obermair GJ, Stefan E, Engel J, Striessnig J.

Pflugers Arch. 2020 Jan;472(1):3-25. doi: 10.1007/s00424-019-02338-4. Epub 2019 Dec 17.

 

STAC proteins associate to the IQ domain of CaV1.2 and inhibit calcium-dependent inactivation.

Campiglio M, Costé de Bagneaux P, Ortner NJ, Tuluc P, Van Petegem F, Flucher BE.

Proc Natl Acad Sci U S A. 2018 Feb 6;115(6):1376-1381. doi: 10.1073/pnas.1715997115. Epub 2018 Jan 23.

 

Lower affinity of isradipine for L-type Ca²⁺ channels during substantia nigra dopamine neuron-like activity: implications for neuroprotection in Parkinson's disease.

Ortner NJ, Bock G, Dougalis A, Kharitonova M, Duda J, Hess S, Tuluc P, Pomberger T, Stefanova N, Pitterl F, Ciossek T, Oberacher H, Draheim H, Kloppenburg P, Liss B, Striessnig J.

J Neurosci. 2017 Jul 12;37(28):6761-6777. doi: 10.1523/JNEUROSCI.2946-16.2017. Epub 2017 Jun 7.

 

A Polybasic Plasma Membrane Binding Motif in the I-II Linker Stabilizes Voltage-gated CaV1.2 Calcium Channel Function.

Kaur G, Pinggera A, Ortner NJ, Lieb A, Sinnegger-Brauns MJ, Yarov-Yarovoy V, Obermair GJ, Flucher BE, Striessnig J.

J Biol Chem. 2015 Aug 21;290(34):21086-100. doi: 10.1074/jbc.M115.645671. Epub 2015 Jun 22.

 

L-type calcium channels as drug targets in CNS disorders.

Ortner NJ, Striessnig J.

Channels (Austin). 2016;10(1):7-13. doi: 10.1080/19336950.2015.1048936. Epub 2015 Jun 3. Review.

 

Pharmacology of L-type Calcium Channels: Novel Drugs for Old Targets?

Striessnig J, Ortner NJ, Pinggera A.

Curr Mol Pharmacol. 2015;8(2):110-22. Review.

 

Pyrimidine-2,4,6-triones are a new class of voltage-gated L-type Ca²⁺ channel activators.

Ortner NJ, Bock G, Vandael DH, Mauersberger R, Draheim HJ, Gust R, Carbone E, Tuluc P, Striessnig J

Nat Commun. 2014 Jun 19;5:3897. doi: 10.1038/ncomms4897.

 

C-terminal modulatory domain controls coupling of voltage-sensing to pore opening in Cav1.3 L-type Ca²⁺ channels.

Lieb A, Ortner NJ, Striessnig J

Biophys J. 2014 Apr 1;106(7):1467-75. doi: 10.1016/j.bpj.2014.02.017.

 

 

 

 nach oben